Recent development of monoamine oxidase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 12, 2005, Pages 1763-1782

  Bolasco, Adriana ^a   Fioravanti, Rossella ^b   Carradori, Simone ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

Alzheimer's disease; Amido propargylamine; Anxiety; Cinnamide; Dementia; Depression; Diterpene; Fluorobenzamide; Imidazole; Isoindole; Isoquinoline; N acylamminoaryl derivative; Oxazole; Parkinson's disease; Phenanthrene; Phthalimide; Pyridine; Pyrrolidine; Thiazole

Indexed keywords

2 PYRROLIDONE DERIVATIVE; 2,3 DIHYDROISOINDOL 1 ONE DERIVATIVE; 3 PHENYLACRYLAMIDE DERIVATIVE; 3 PHENYLPROPIONAMIDE DERIVATIVE; 3 PHENYLPROPYNAMIDE DERIVATIVE; 4 PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVE; ACRYLAMIDE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENZAMIDE DERIVATIVE; BENZAZEPINE DERIVATIVE; BENZYL DERIVATIVE; CHOLINESTERASE INHIBITOR; DITERPENE; ETHER DERIVATIVE; INDAN DERIVATIVE; ISOINDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N ACYLAMINO ACID; NEW DRUG; PHENANTHRENE DERIVATIVE; PHTHALIMIDE DERIVATIVE; PROPARGYLGLYCINE; PROPIONAMIDE DERIVATIVE; PROPYLAMINE; PYRIDINE DERIVATIVE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ALCOHOLISM; ALZHEIMER DISEASE; DEAMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME STRUCTURE; HUMAN; IC 50; INFLAMMATION; MENTAL DISEASE; MITOCHONDRIAL MEMBRANE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATENT; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; STRUCTURE ACTIVITY RELATION;

EID: 30344432647     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.12.1763     Document Type: Review

References (56)

1. SINGER TP, VON KORFF RW, MURPHY DL: In: Monoamine Oxidase: Structure, Function and Altered Functions. Academic, New York, USA (1979).
2. MURE M, MILLS SA, KLINMAN JP: Catalytic mechanism of the topa quinone containing copper amine oxidases. Biochemistry (2002) 41(30):9269-9278.
3. JOHNSTON JP: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. (1968) 17:1285-1297.
4. KNOLL J, MAGYAR K: Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. (1972) 5:393-408.
5. BACH AW, LAN NC, JOHNSON DL et al.: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA (1988) 85:4934-4938.
6. WOUTERS J: Structural aspects of of monoamine oxidase and its reversible inhibition. Curr. Med. Chem. (1998) 5:137-162.
7. WALKER MC, EDMONDSON DE: Structure-activity relationships in the oxidation of benzylamine analogues by bovine liver mitochondrial monoamine oxidase B. Biochemistry (1994) 33:7088-7098.
8. MILLER JR, EDMONDSON DE: Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry (1999) 38:13670-13683.
9. SILVERMAN RB, HOFFMAN SJ, CATUS WB: A mechanism for mitochondrial monoamine oxidase catalyzed amine oxidation. J. Am. Chem. Soc. (1980) 102:7126-7128.
10. KIM JM, BOGDAN MA, MARIANO PS: Mechanistic analysis of the 3-methyllumiflavin-promoted oxidative deamination of benzylamine. A potential model for monoamine oxidase catalysis. J. Am. Chem. Soc. (1993) 115:10591-10595.
11. LU X, RODRÌGUEZ M, GU W, SILVERMAN RB: Inactivation of mitochondrial monoamine oxidase B by methylthio-substituted benzylamines. Bioorg. Med. Chem. (2003) 11(20):4423-4430.
12. CESURA AM, PLETSCHER A: The new generation of monoamine oxidase inhibitors. Prog. Drug Res. (1992) 38:171-257.
13. SAURA J, LUQUE JM, CESURA AM et al.: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience (1994) 62:15-30.
14. AMREIN R, MARTIN JR, CAMERON AM: Moclobemide in patients with dementia and depression. Adv. Neurol. (1999) 80:509-519.
15. CHIBA K, TREVOR A, CASTAGNOLI N: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. (1984) 120:574-578.
16. FRITZ RR, ABELL CW, PATEL NT, GESSNER W, BROSSI A: Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. FEBS Lett. (1985) 186:224-228.
17. GRIMSBY J, TOTH M, CHEN K et al.: Increased stress response and β-phenylethylamine in MAOB-deficient mice. Nat. Genet. (1997) 17:206-210.
18. DE ZUTTER GS, DAVIS RJ: Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl. Acad. Sci. USA (2001) 98:6168-6173.
19. MCMILLAN FH, LEONARD F, MELTZER RI, KING JA: Antitubercular substances. II. Substitution products of isonicotinic hydrazide. J. Am. Pharm. Assoc. (1953) 42:457-464.
20. FOWLER CJ, ORELAND L, CALLINGHAM BA: The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. J. Pharm. Pharmacol. (1981) 33:341-347.
21. KNOLL J, ECSERY Z, KELEMEN K, NIEVEL J, KNOLL B: Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmachodyn. Ther. (1965) 155:154-164.
22. FINBERG J P, TENNE M, YOUDIM MB: Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol. (1981) 73(1):65-74.
23. WEINSTOCK M, BEJAR C, WANG RH et al.: TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. (2000) Suppl.60:157-169.
24. YOUDIM M B, HOLMAN B: The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. J. Neural Tranm. (1975) 37(1):11-24.
25. MOUREAU F, WOUTERS J, VERCAUTEREN DP et al.: A reversible monoamine oxidase inhibitor, toloxatone: structural and electronic properties. Eur. J. Med. Chem. (1992) 27:939-948.
26. MOUREAU F, WOUTERS J, VERCAUTEREN DP et al.: A reversible monoamine oxidase inhibitor, toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD). Eur. J. Med. Chem. (1994) 29:269-277.
27. MOUREAU F, WOUTERS J, DEPAS M et al.: A reversible monoamine oxidase inhibitor, toloxatone: comparison of its physicochemical properties with those of other inhibitors including brofaromine, harmine, R40519 and moclobemide. Eur. J. Med. Chem. (1995) 30:823-838.
28. RABASSEDA X, SORBERA LA, CASTANER J: Befloxatone (MD-370503): antidepressant, MAO-A [monoamine oxidase A] inhibitor. Drugs Fut. (1999) 24:1057-1067.
29. WOUTERS J, MOUREAU F, EVRARD G et al.: A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action. Bioorg. Med. Chem. (1999) 7:1683-1693.
30. BINDA C, NEWTON-VINSON P, HUBALEK F, EDMONDSON DE, MATTEVI A: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. (2002) 9:22-26.
31. EDMONDSON D E, BINDA C, MATTEVI A: The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology (2004) 25:63-72.
32. DE COLIBUS L, LI M, BINDA C, LUSTIG A, EDMONDSON DE, MATTEVI A: Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. (2005) Proc. Natl. Acad. Sci. USA 102(36):12684-12689.
33. MA J, YOSHIMURA M, YAMASHITA E, NAKAGAWA A, ITO A, TSUKIHARA T: Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. Biol. (2004) 338:103-114.
34. HUBALEK F, BINDA C, KHALIL A et al.: Demonstration of isoleucine 199 as a structural determinant for selective inhibition of human monoamine oxidase B by specific reversibile inhibitors. J. Biol. Chem. (2005) 280(16):15761-15766.
35. JONES TZ, FLEMING P, EYERMANN CJ, GRAVESTOCK MB, RAMSAY RR: Orientation of oxazilidinones in the active site of monoamine oxidase. Biochem. Pharmacol. (2005) 70:407-416.
36. FREDERICK R, NORBERG B, DURANT F, OOMS F, WOUTERS J: Three 5H-indeno[1,2-c]pyridazin-5-one derivatives, potent type-B monoamine oxidase inhibitors. Acta Crystallogr. C (2004) 60:623-626.
37. 2A receptors and as inhibitor of MAO-B. Acta Crystallogr. C (2005) 61:531-532.
38. BINDA C, HUBALEK F, LI M, HERZIG Y et al.: Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem. (2004) 47:1767-1774.
39. GHANBARPOUR A, HADIZADEH F, PIRI F, RACHIDI-RANJBAR P: Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues. Pharm. Acta Helv. (1997) 72:119-122.
40. SCHLAEGER EJ, CHRISTENSEN K: Transient gene expression in mammalian cells grown in serum-free suspension culture. Cytotechnology (1988) 15:1-13.
41. ZHOU M, PANCHUCK-VOLOSHINA N: A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal. Biochem. (1997) 253:169-174.
42. KIM H, SABLIN SO, RAMSAY RR: Inhibition of monoamine oxidase A by β carboline derivatives. Arch. Biochem. Biophys. (1997) 337:137-142.
43. 3H]Harmaline as a specific ligand of MAO A. I. Properties of the active site of MAO A from rat and bovine brains. J. Neurochem. (1979) 32(6):1817-1827.
44. BEMBENEK ME, ABELL CW, CHRISEY LA, ROZWADOWSKA MD, GESSNER W, BROSSI A: Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optical active 1,2,3,4-tetrahydro-,3,4-dihydro-, and fully aromatic isoquinoline. J. Med. Chem. (1990) 33:147-152.
45. 3H]Ro 41-1049 to the active site of monoamine oxidase-A. Molec. Pharmacol. (1990) 37:358-366.
46. 3H]Ro 19-6327: a reversible ligand and affinity-labeling probe for monoamine oxidase-B. Eur. J. Pharmacol. (1989) 162:457-465.
47. YOUDIM MB, BAR-AM O, YOGEV-FALACH M et al.: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. (2004) 79:172-179.
48. YOUDIM MB, FRIDKIN M, ZHENG H: Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. (2005) 126:317-326.
49. YOUDIM M B H, BUCCAFUSCO JJ: CNS target for multifunctional drugs in the treatment of Alzheimer's and Parkinson's disease. J. Neural Transm. (2005) 112:519-537.
50. MANDEL S, WEINREB O, AMIT T, YOUDIM MB: Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Rev. (2005) 48:379-387.
51. YOUDIM MB, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26:27-35.
52. RANDO RR, EIGNER A: The pseudoirreversible inhibition of monoamine oxidase by allylamine. Mol. Pharmacol. (1977) 13:1005-1013.
53. SILVERAMN RB, HIEBERT CK, VASQUEZ ML: Inactivation on monoamine oxidase by allylamine does not results in flavin attachment. J. Biol. Chem. (1985) 260:14648-14652.
54. BEY P, FOZARD J, LACOSTE JM, McDONALD IA, ZREIKA M, PALFREYMAN MG: (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme activated inhibitor of type B monoamine oxidase. J. Med. Chem. (1984) 27:9-10.
55. CHRISTENSEN AV, FJALLAND B, PEDERSEN V, DANNESKIOLD-SAMSOEE P, SVENDSEN O: Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties. Eur. J. Pharmacol. (1977) 41(2):153-62.
56. SIEGMUND EA, CADMUS RA, LU G: Screening of analgesics including aspirin type compound based upon the antagonism of chemically induced writhing in mice. J. Pharmacol. Exp. Therap. (1957) 119:421-425.